The short version
Wegovy launched in 2021 and has had three more years than Zepbound to land on insurance formularies. Coverage is broader, prior-auth criteria are better documented and the cash-pay path through NovoCare ($199-$499/mo) has stabilised. If you specifically want brand Wegovy and not compounded semaglutide, you're looking for either an in-network insurance program that runs the PA or a clean cash-pay route through NovoCare-aware prescribers.
What we considered
- Active prescribing of brand Wegovy (not just compounded)
- Prior authorization handling on commercial insurance
- NovoCare cash-pay coordination if insurance doesn't cover
- Speed and cost predictability
Top pick: PlushCare
Best for insurance-covered brandedPlushCareInsurance-first telehealth. As low as $25/mo for Wegovy if your plan covers it. Starts From
$19.99/mo+ medication separatePlushCare runs your real commercial insurance benefits with active PA on Wegovy. If you have employer coverage that includes obesity treatment, this is the fastest path from intake to a $25-$50 copay.
Read the full PlushCare review →
Other strong picks
Form HealthForm Health's obesity-medicine specialists write the strongest PA letters we've seen across the chart, with the highest approval rate on Wegovy step-therapy cases. Starts From
$299/mo+ med separateRo BodyRo Body offers brand Wegovy through NovoCare's cash-pay channel at $299-$499/mo, plus optional insurance routing if your plan covers it. Starts From
$39/mo+ med separateKnownwellKnownwell handles Wegovy as part of a full obesity-medicine workup. Better fit if you have comorbidities to coordinate. Starts From
Insurance-billed+ med separate9amHealth9amHealth specifically targets patients with type 2 diabetes, prediabetes or cardiovascular risk, where Wegovy PA approval rates are highest. Starts From
$25/mo+ med separateWhy you can trust GLP ChartSame scoring framework applied to every program. No paid placements. No removal of unfavorable information at advertiser request. Pricing is pulled from each program's public-facing page weekly.